How to Evaluate Abnormal Uterine Bleeding in Stable Patients

Abnormal uterine bleeding (AUB) represents one of the most common presentations in gynecology practice, accounting for more than 70% of gynecologic consultations in perimenopausal and postmenopausal years. For clinicians evaluating stable patients with AUB, a systematic approach ensures accurate diagnosis while avoiding unnecessary testing.

The American College of Obstetricians and Gynecologists (ACOG) and other professional organizations provide evidence-based guidance for evaluating AUB. This guide synthesizes these recommendations into a practical clinical workflow for stable patients.

Understanding Abnormal Uterine Bleeding

Definition

Abnormal uterine bleeding refers to menstrual flow outside of normal volume, duration, regularity, or frequency. Compared with typical menses, AUB may present with:

• Heavy menstrual bleeding (excessive volume)
• Prolonged bleeding duration
• Irregular cycle timing
• Intermenstrual bleeding
• Postmenopausal bleeding (any bleeding 12+ months after final menstrual period)

The PALM-COEIN Classification System

The FIGO PALM-COEIN system classifies AUB etiologies into structural and non-structural categories:

Structural causes (PALM):

• P - Polyp (endometrial or cervical)
• A - Adenomyosis
• L - Leiomyoma (fibroids)
• M - Malignancy and hyperplasia

Non-structural causes (COEIN):

• C - Coagulopathy
• O - Ovulatory dysfunction
• E - Endometrial
• I - Iatrogenic
• N - Not otherwise classified

Step-by-Step Evaluation Guide

1. Initial Assessment and Stabilization

Even in stable patients, begin with a rapid assessment to confirm clinical stability:

Vital signs: Check blood pressure, heart rate, and orthostatic changes to rule out early hypovolemia.

Signs of significant blood loss:

• Pallor (conjunctival, palmar)
• Tachycardia
• Fatigue or dizziness
• Shortness of breath on exertion

If the patient shows any signs of hemodynamic instability, initiate emergency protocols including IV access, fluid resuscitation, and blood transfusion as needed.

2. Exclude Pregnancy

Pregnancy testing is mandatory for all patients of reproductive age with AUB, even in adolescents and perimenopausal women. Pregnancy complications including ectopic pregnancy, miscarriage, and gestational trophoblastic disease can present as abnormal bleeding.

Use a urine or serum hCG test. A negative result allows you to proceed with the non-pregnant AUB evaluation algorithm.

3. Obtain Detailed Menstrual History

A thorough menstrual history often suggests the underlying etiology and guides test selection:

Key questions to ask:

• "When did your last normal period occur?"
• "How has your bleeding pattern changed?"
• "How many pads or tampons do you use on the heaviest day?"
• "Do you pass clots? How large?"
• "Do you bleed between periods or after intercourse?"
• "Are your cycles regular or irregular?"
• "When was your last menstrual period?"

Pattern recognition:

• Regular cycles with heavy/prolonged bleeding: Suggests structural abnormalities (polyps, fibroids, adenomyosis)
• Irregular bleeding or amenorrhea: Often indicates ovulatory dysfunction
• Postmenopausal bleeding: Requires urgent evaluation for endometrial pathology

Associated symptoms:

• Pelvic pain or pressure (fibroids, adenomyosis)
• Dysmenorrhea (endometriosis, adenomyosis)
• Hirsutism or acne (PCOS, ovulatory dysfunction)
• Galactorrhea (hyperprolactinemia)
• Easy bruising or bleeding from other sites (coagulopathy)

4. Review Medical and Medication History

Medical conditions associated with AUB:

• Thyroid disorders
• Polycystic ovary syndrome (PCOS)
• Obesity (unopposed estrogen exposure)
• Diabetes mellitus
• Liver or kidney disease
• Bleeding disorders (von Willebrand disease, especially in adolescents)

Medications that can cause AUB:

• Hormonal contraceptives (especially during first 3 months)
• Anticoagulants (warfarin, heparin, direct oral anticoagulants)
• Antiplatelet agents (aspirin, clopidogrel)
• SSRIs and SNRIs
• Tamoxifen and other SERMs
• Chemotherapeutic agents

5. Perform Focused Physical Examination

General examination:

• Vital signs including orthostatics if indicated
• BMI calculation (obesity increases endometrial cancer risk)
• Signs of anemia (pallor, tachycardia)
• Signs of hyperandrogenism (hirsutism, acne, male-pattern baldness)
• Thyroid enlargement or nodules
• Skin findings (bruising, petechiae suggesting coagulopathy)

Pelvic examination:

• Speculum exam: Visualize cervix and vagina to confirm bleeding source, rule out cervical or vaginal lesions, polyps, or trauma
• Bimanual exam: Assess uterine size, shape, contour, and mobility; evaluate for adnexal masses or tenderness
• Uterine findings: Enlarged, irregular uterus suggests fibroids; boggy, tender uterus suggests adenomyosis; normal-sized uterus with AUB suggests endometrial pathology or ovulatory dysfunction

6. Order Appropriate Laboratory Tests

Initial laboratory evaluation for all patients:

Additional tests based on clinical presentation:

7. Perform Pelvic Imaging

Transvaginal ultrasound is the first-line imaging modality for most patients with AUB. It provides detailed visualization of:

• Endometrial thickness and texture
• Uterine structure (fibroids, adenomyosis)
• Ovarian morphology (polycystic ovaries, masses)
• Presence of polyps or other intracavitary lesions

Endometrial thickness considerations:

• In reproductive-age women, endometrial thickness varies with cycle phase
• In postmenopausal bleeding, endometrial thickness >4mm warrants further evaluation
• ACOG's 2026 updated guidance recommends combining transvaginal ultrasound with endometrial tissue sampling for most patients with postmenopausal bleeding

Saline infusion sonohysterography (SIS): May be performed if standard ultrasound is inconclusive or to better characterize intracavitary lesions.

8. Determine Need for Endometrial Biopsy

Endometrial biopsy is indicated for:

• All patients aged 45 years and older with AUB
• Patients younger than 45 with:
  • History of unopposed estrogen exposure (obesity, PCOS)
  • Failed medical management
  • Persistent AUB despite treatment
  • Postmenopausal bleeding
  • Lynch syndrome or family history of endometrial/colon cancer
  • Tamoxifen use

Methods:

• Office endometrial biopsy (Pipelle) - first line for most patients
• Hysteroscopy with directed biopsy - for focal lesions or inadequate office biopsy
• Dilation and curettage (D&C) - when office biopsy is not feasible or inadequate

Note on postmenopausal bleeding: ACOG's 2026 updated guidance emphasizes that relying on ultrasound alone may miss significant pathology. The combination of transvaginal ultrasound and endometrial tissue sampling is recommended for most patients with postmenopausal bleeding to reduce the risk of missing endometrial cancer.

9. Additional Diagnostic Procedures

Hysteroscopy: Direct visualization of the endometrial cavity. Indicated when:

• Intracavitary pathology is suspected
• Office biopsy is inadequate or inconclusive
• Treatment of polyps or submucosal fibroids is planned

MRI: Reserved for complex cases or surgical planning when fibroids or adenomyosis are suspected and ultrasound is inconclusive.

Red Flags

Seek urgent evaluation or referral when any of the following are present:

• Hemodynamic instability: Hypotension, tachycardia, signs of shock
• Severe anemia: Hemoglobin <7 g/dL or symptomatic anemia
• Postmenopausal bleeding: Any bleeding after 12 months of amenopause requires prompt evaluation
• Suspected malignancy: Postmenopausal bleeding, endometrial thickness >4mm in postmenopausal women, failed medical management in high-risk patients
• Coagulopathy: Personal or family history of bleeding disorder, especially in adolescents with severe bleeding
• Pregnancy-related bleeding: Positive pregnancy test with bleeding (rule out ectopic pregnancy)
• Rapidly enlarging uterine mass: Concern for leiomyosarcoma (rare)

Common Questions

When should I refer a patient with AUB to a gynecologist?

Refer patients when: endometrial biopsy is indicated but cannot be performed in office, imaging reveals complex structural abnormalities, medical management fails, malignancy is suspected, or the patient desires surgical management. Postmenopausal bleeding warrants referral for expedited evaluation.

How do I differentiate ovulatory from anovulatory bleeding?

Ovulatory bleeding typically presents as regular cycles with predictable timing. Anovulatory bleeding is characteristically irregular, unpredictable, and may alternate between amenorrhea and heavy bleeding. Mid-luteal serum progesterone (>3 ng/mL) confirms ovulation. Ovulatory dysfunction is common in adolescents, perimenopausal women, and patients with PCOS or thyroid disorders.

Is routine endometrial sampling necessary in reproductive-age women?

No. Endometrial biopsy is not routinely indicated in reproductive-age women under 45 without risk factors. Reserve biopsy for patients with persistent AUB, failed medical management, or risk factors for unopposed estrogen exposure (obesity, PCOS, tamoxifen use, Lynch syndrome).

What is the role of transvaginal ultrasound in AUB evaluation?

Transvaginal ultrasound is the first-line imaging modality for AUB. It detects structural abnormalities including polyps, fibroids, and adenomyosis. In postmenopausal bleeding, endometrial thickness ≤4mm has high negative predictive value for endometrial cancer, though ACOG's 2026 guidance recommends combining ultrasound with tissue sampling for most patients.

Protocol Summary

• Confirm hemodynamic stability and rule out pregnancy with hCG testing
• Obtain detailed menstrual history including pattern, duration, and volume
• Review medical history and medications for contributing factors
• Perform physical and pelvic examination to identify structural causes
• Order CBC, TSH, and prolactin; add ferritin if anemic
• Perform transvaginal ultrasound to evaluate uterine and ovarian structure
• Obtain endometrial biopsy for patients ≥45 years or younger patients with risk factors
• Refer to gynecology for complex cases, failed medical management, or suspected malignancy

How Rovetia Helps

Rovetia streamlines AUB evaluation by enabling structured documentation of menstrual history, bleeding patterns, and risk factors directly in the patient's clinical record. The AI-powered system extracts key findings from clinician notes and patient-reported data, automatically flagging patients who meet criteria for endometrial biopsy or referral. This helps gynecologists ensure no high-risk patient falls through the cracks during evaluation.

Sources

• ACOG Publishes Updated Guidance on Evaluation of Postmenopausal Bleeding
• Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women | ACOG
• Abnormal Uterine Bleeding (AUB) - Merck Manual Professional Edition

Related Posts

• Recurrent UTI in Women: Gynecology Evaluation Guide
• How to document patient history in primary care?